cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Mohammad Saifur Rohman
Contact Email
hsj@ub.ac.id
Phone
+628973247705
Journal Mail Official
hsj@ub.ac.id
Editorial Address
Department of Cardiology and Vascular Medicine, Dr. Saiful Anwar General Hospital, 3rd Floor CVCU Jl. Jaksa Agung Suprapto No. 2, Malang, Indonesia
Location
Kota malang,
Jawa timur
INDONESIA
Heart Science Journal
Published by Universitas Brawijaya
ISSN : 27219976     EISSN : 27219984     DOI : http://dx.doi.org/10.21776/ub.hsj.2020.001.01
Core Subject : Health, Science,
Health Professions Immunology & microbiology Medicine & Pharmacology
HEART SCIENCE is the official open access journal of Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia. The journal publishes articles three times per year in January, May, and September. The journal is a peer reviewed publication and accepts articles for publication from across the world. HEART SCIENCE accepts and publishes articles in the English language only. The primary goal of this journal is to publish clinical and basic research relevant to cardiovascular medicine. The journal covers the following topics: clinical cardiology, interventional cardiology, intensive and acute cardiovascular care, vascular diseases, non-invasive cardiology, pediatric cardiology, cardiac nuclear medicine imaging, arrhythmia, cardiac prevention and rehabilitation, and cardiac surgery. Animal studies are also considered for publication in HEART SCIENCE. To serve the interest of both practicing clinicians and researchers, the journal provides platform or forum for research scholars, intellectuals, and cardiologists to reveal their views and research work for dialogue, education, and interaction to the entire world. HEART SCIENCE publishes original research, reviews, brief reports, case reports, case series, editorial, and commentary. HEART SCIENCE also publishes the special issues and abstracts of papers presented at the annual meeting of the Cardiological Society of Malang.
Arjuna Subject : Kedokteran - Cardiology and Cardiovascular Medicine
Articles 302 Documents
 4   5   6   7   8 
Venous Thromboembolism Prevention in COVID-19: A Review of Latest Evidences Muchammad Dzikrul Haq Karimullah; Nisa Amnifolia Niazta; Hiradipta Ardining
Heart Science Journal Vol 1, No 3 (2020): Management of Coronary Artery Disease: From Risk Factors to The Better Long-Term
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2020.001.03.3

Abstract

COVID-19 has become major public health problems, with new cases and deaths growing around the world. COVID-19 has been reportedly associated with hypercoagulable state which can lead to venous thromboembolism (VTE) formation. This condition is also associated with worse outcomes in COVID-19 patients, therefore, it is critical for clinicians to identify this condition and manage it accordingly. VTE formation in COVID-19 occurs through several mechanisms, such as inflammatory reaction leading to hypercoagulable state and vascular dysfunction, direct vascular injury by the virus, and immobilization of the patients. The rate of VTE formation is as high as 31% in ICU patients and 9.2% in general wards patients, and it is also associated with poorer prognosis. Thromboprophylaxis with heparin, particularly low molecular weight heparin (LMWH), has been shown to improve the prognosis in these patients. A careful individual assessment is required to determine which patients will benefit from this therapy, as there are still no sufficient prospective trials to establish guidelines for VTE thromboprophylaxis in COVID-19. The assessment includes laboratory parameters such as PT, platelet count, D-dimer, fibrinogen, and other risk factors incorporated in PADUA risk assessment model (RAM), versus the risk of bleeding incorporated in IMPROVE bleeding RAM.
The Role of Garcinia Mangostana Pericarp Extract as Antioxidant to Inhibit Atherosclerosis Process in High Risk Framingham Score Patient; Original Article Aris Munandar ZI; Djanggan Sargowo; Ardian Rizal; Cholid Tri Tjahjono; Sasmojo Widito; Anna Fuji Rahimah
Heart Science Journal Vol 2, No 1 (2021): How to Diagnose Heart Failure and Deal with The Treatment Complexity
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2021.002.01.04

Abstract

Atherosclerosis is the pivotal role of cardiovascular disease (CVD) involving oxidative stress dan inflammation. Garcinia has anti-oxidant property for years. This study was performed to explore the role of α-Mangostin of Garcia Mangostana Pericarp Extract as an antioxidant in inhibiting atherosclerotic process in patients with high-risk Framingham score. Methods: This prospective cohort design was led in 90 grown-ups with high hazard cardiovascular score which were resolved dependent on Framingham criteria, age 50–70 years of age. The patients were divided into two groups. One group was administered  2520 mg/day Garcinia mangostana Linn extracts (GMLE) in 3 divided doses for 90 days and the other group was administered a placebo. Parameters were Nitric Oxide (NO), Superoxide Dismutase (SOD) and Malondialdehyde (MDA), measured at baseline and after 90 days of treatment. An Independent T-test was performed for normally distributed data and the Mann-Whitney test was performed for abnormally distributed data with a significance level of p≤0.05.Results: Among the 77 subjects, we found that the plasma, MDA, concentration was significantly decreased compared with placebo 0,29±0.5 vs -0.04±0.25, respectively p = 0.011). SOD level significantly decreased in GMLE patients compared with placebo patients (0,17±0.79 vs -0.27±0.67, respectively, p=0.010) and we found that there was slightly increased in nitric oxide (NO), but no significantly compared with placebo 4.34±10.01 and 2.35±7.39, respectively, p = 0.37).Conclusion: Garcinia mangostana pericarp extract has an antioxidant effect that significantly inhibit atherosclerosis process in high-risk Framingham score patients
Impacts of Residual SNYTAX Score on The Clinical Outcomes following Percutaneous Coronary Intervention in Chronic Coronary Syndrome Patients Wira Kimahesa Anggoro; Mohammad Saifur Rohman; Heny Martini; Pawik Supriadi; Cholid Tri Tjahjono; Yoga Waranugraha
Heart Science Journal Vol 2, No 3 (2021): The Science and Art of Myocardial Revascularization
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2021.002.03.4

Abstract

Background: The residual SYNTAX score (RSS) can be used to measure the residual stenosis severity and complexity. The prognostic role of RSS in CCS patients is still unknown. We purposed to investigate the impact of RSS on the clinical outcomes following PCI in CCS patients. Methods: A prospective cohort study was performed. Based on the residual SYNTAX score, patients were divided into three groups: RSS 0, RSS 0 to 9.5, and RSS >9.5. The primary outcome was patient-oriented composite endpoint (POCE), including repeat revascularization, myocardial infarction, and all-cause mortality. Results: After 1-year follow-up period, patients in RSS >9.5 group revealed the greater POCE (4.3% vs. 6.4% vs. 23.9%; p = 0.016) than others. The repeat revascularization rate also was greater in the RSS >9.5 group (0.0% vs. 6.4% vs. 19.6%; p = 0.012). However, the hospitalization due to angina rates in all groups was not significantly different (4.3% vs. 4.2% vs. 4.3%; p = 1.000). The multivariate analysis revealed that RSS >9.5 was the strong predictor for repeat revascularization during 1 year follow-up (Odds ratio [OR] = 9.605; 95% confidence interval [CI] = 1.207 - 76.458; p = 0.033). Conclusion: The greater RSS was associated with the higher 1-year POCE and repeat revascularization rate in CCS patients. The high RSS was also the strong predictor for 1-year repeat revascularization for CCS patients. 
Leukocytosis as The Short-Term Predictor for Mortality in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention Setyasih Anjarwani; Krishna Ari Nugraha; Muhammad Rizki Fadlan
Heart Science Journal Vol 1, No 4 (2020): Acute Coronary Syndrome in Daily Practice : Diagnosis, Complication, and Managem
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2020.001.04.04

Abstract

AbstractBackground: In daily clinical practice, leukocyte count is the most common and simple inflammation parameter. Moreover, its role in predicting acute coronary syndrome (ACS) patients' clinical outcomes and prognosis is still conflicting. This study aimed to assess the role of leukocytosis as the predictor of mortality in ACS patients undergoing percutaneous coronary intervention (PCI).Method: This single-center retrospective cohort study used the STEMI registry data in Saiful Anwar General Hospital, Malang, Indonesia, from January to July 2019. The exposure was the leucocyte count during hospital admission and the outcome was the 30-day mortality following PCI procedure. The receiver-operating characteristic (ROC) curve was used to determine leucocyte count cut-off pint, sensitivity, and specificity.Result: The best leukocyte count cut-off value was 12300/µL, with the area under the curve (AUC) of 0.702 (95% CI 0.575 - 0.83), sensitivity of 71.4%, and specificity of 61.3%. Leukocytosis increased the risk of 30-day mortality (74.5% vs 42.4%; OR = 3.958; 95% CI = 1.518-10.25; p = 0.014). Survival rate within 30-day after PCI was lowered in leukocytosis group (the Log-Rank p = 0.002). The difference became apparent after day five post-PCI. Conclusion: Leukocytosis during hospital admission is associated with increased mortality in ACS patients undergoing PCI. Leucocytosis is a good predictor of mortality within 30 days after PCI in this population. Keywords: leukocytosis, acute coronary syndrome, percutaneous coronary intervention, mortality
Common Femoral Artery Aneurysm: A Challenging Diagnostic and Treatment of a Rare Case Ayu Asri Devi Adityawati; Novi Kurnianingsih; Budi Satrijo; Indra Prasetya
Heart Science Journal Vol 2, No 2 (2021): Dealing with Vascular Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2021.002.02.7

Abstract

BACKGROUND: Aneurysm of peripheral artery is a rare vascular pathology, especially aneurysm in common femoral artery. Here, we presented a case report of right common femoral artery aneurysm caused by infectionCASE REPORT: a 76-year-old man referred to our hospital with pulsatile groin mass at his right thigh. He had no prior history of surgery or traumas, but he has been treated in private hospital due to septic condition, hypertension, and diabetes mellitus type II. Based on findings from physical examination and radiology examination, a diagnosis of common femoral artery aneurysm was made. The patient was referred to Cardiovascular and Thoracic Surgeon Department and scheduled for routine surgery, but on third day of admission patient became hemodynamically unstable and on re-examination it was found that the aneurysm had been ruptured. Emergency surgery was conducted on that day. During surgery patient was hemodynamically stable with PRC transfusion.DISCUSSION: Aneurysms can occur in almost any artery in the body. Femoral artery aneurysm was rare. Diagnostic procedure with various modalities were needed to establish a precise diagnosis for patient which come with swelling in his/her lower extremity. Doppler ultrasound was conducted in order to find a saccular mass with neck and a yin and yang phenomenon, which can narrow down the differential diagnosis to pseudoaneurysm or aneurysm. Subsequent CT angiography clearly confirmed the involvement of 3 layer arterial wall as a sign of an aneurysm. Femoral artery aneurysms (FAA) may be caused by weakening of the arterial wall due to atherosclerosis or mycotic aneurysm. Surgical repair of aneurysm is an option when symptomatic and that should also be considered when there is ongoing hemodynamic instability or limb ischemia.CONCLUSION: The common femoral artery aneurysm aren’t common. It is very rarely to be isolated aneurysm and usually don’t tend to be rupture. Whenever a femoral artery aneurysm is found, search and follow-up for other aneurysms should take place. Annual follow-up is recommended. Straightforward surgical management brings good results in this group of patient. Keywords: Femoral artery aneurysm, Common femoral artery aneurysm, Isolated aneurysm, Mycotic aneurysm
Acute Aorto-Illiac Occlusion with Bilateral Limb Ischemia Underwent Direct Catheter Thrombolysis in Older Patient: A Case Report Irma Kamelia; Novi Kurnianingsih
Heart Science Journal Vol 2, No 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2021.002.04.7

Abstract

BACKGROUND: Peripheral arterial diseases could be a major burden for the health system with a wide clinical spectrum from symptomatic to the limb threatening. A sudden onset of limb deteriorations represent a vascular emergency and need a proper treatment to limb preservation and life-saving. It is still challenging to choose a proper management to reduce morbidity and mortality, despite a various advance of diagnostic and therapeutic tools were available.CASE SUMMARY: A 70-years-old man came to our hospital with chief complaint leg pain at both of his legs, suddenly since 18 hours before admission. He had parasthesia and paralysis in both of his legs. And the doppler ultrasonography result was occlusion proximal to the right and left common iliac artery. Then we performed percutaneous intra-arterial thrombolysis using streptokinase and had gastrointenstinal bleeding as an adverse event.DISCUSSION: This case report provides an example of management acute limb ischemia in developing country with a limited source in comparison with the recent guideline and study. Further research is needed to establish a proper management to reduce morbidity and mortality in these cases.
Current Anticoagulation Recommendation for COVID-19 Patients Indra Prasetya
Heart Science Journal Vol 2, No 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2021.002.04.1

Abstract

Thromboembolic events in COVID-19 patients can be one of the factors that aggravate the disease and increase mortality. When severe hypoxemia and hypotension occur in COVID-19 patients, the possibility of embolism should be considered. As a result, anticoagulant therapy in COVID-19 patients has an essential role in lowering disease severity and mortality. Many studies report that giving anticoagulants to COVID-19 patients can reduce mortality. Therefore, it is important to understand the role and use of anticoagulant therapy in cases of COVID-19. Several guidelines that have been issued by several health organizations in the world and Indonesia can be used as guidelines for clinicians to start anticoagulant therapy in cases of COVID-19. Various anticoagulant drug regimens have also been recommended to be used both as prophylaxis and as therapy for thromboembolism that can occur after COVID-19 cases.
Coronavirus Infection Induced Coagulopathy As A Trigger Factor Of Arterial Thrombosis In Patient With Atherosclerotic Risk Factor: A Case Report Irma Kamelia; Heny Martini; Novi Kurnianingsih; Indra Prasetya
Heart Science Journal Vol 2, No 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2021.002.04.8

Abstract

Background : A newly emerging pandemic of Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory coronavirus 2 is responsible for significant morbidity and mortality worldwide. As one of the effects is hematological changes related to the COVID-19 infection causing patient tend to thrombosis than hemorrhagic. Current review of evidence and statements on management of coagulopathy and thrombotic complications related to this novel disease is needs to be exploredCase : Male 53 years old referred from Private Hospital, due to Severe pneumonia due to COVID-19 and Acute Limb Ischemia. This patient was assessed as Pneumonia COVID-19 severe with acute limb ischemia bilateral grade IIB and performed bilateral surgical thrombectomy with antegrade approach using fogarty catheter with the result was thrombus 10cm along the left femoral artery and thrombus 2cm in the right femoral artery. Discussion : With consideration of atherosclerotic diseases in this patient, we decided to give rivaroxaban as an anticoagulant combined with aspilet and statin high dose. But due to lack of source in our hospital, and patient also denied for further management, treatment for the patient cannot be optimal, so the patient discharge with unresolved limb ischemia.Conclusion : This case showed that the increase risk of heparin resistance in SARS-CoV-2 patient, it is recommend- ed to monitor heparin activity of UFH treatment based on anti-Xa levels instead of aPTT alone
The Combination of Oral PDE5-Inhibitor (Sildenafil) And Oral Prostacyclin Analogue (Beraphrost) Therapy for Increasing Quality of Life in Adults with Pulmonary Arterial Hypertension Related to Uncorrected Secundum Atrial Septal Defect Heny Martini; Muhammad Rizki Fadlan; Akhmad Isna Nurudinulloh
Heart Science Journal Vol 2, No 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2021.002.04.5

Abstract

Background : Sildenafil, an oral phosphodiesterase type-5 inhibitor, has vasodilatory effects through a cyclic guanosine 3,5-monophosphate–dependent mechanism, whereas beraprost, an oral prostacyclin analog, induces vasorelaxation through a cAMP-dependent mechanism.Objective : To investigate whether the combination of oral sildenafil and beraprost is superior to sildenafil alone in in adult patients with PAH related uncorrected secundum ASD.Method : Patients with secundum ASD who developed PAH divided into two group. Group A received oral sildenafil 3x40 mg and oral beraphrost 3x20mcg. Group B received oral sildenafil only 3x40 mg in a 12-week. Health-related quality of life (HRQoL) was recorded by patients using the Medical Outcomes Study 36-item short form (SF-36) questionnaires at baseline and after 12 of therapy. Therapy adherence was achieved through a series of phone calls and a four-weekly hospital visit. Every normal follow-up appointment included an examination of side effects and a dosage modification based on the clinical situation.Results : We didn’t found any significant of proportion different in Comorbid condition between groups. Compared with Group B, Group A had increased in physical functioning, Limitation to physical health, Energy fatigue, Pain, and health change (P=0.00, P=0.03, P=0.044, P=0.026, P=0.008, respectively).Conclusion : We suggest that combination between oral sildenafil therapy 40 mg three times per day and Beraphrost 20mcg two times per day significantly increase the HRQOL in PAH patients due to uncorrected secundum ASD.
Management of Antithrombotic Therapy in Post PCI Patient Undergoing Pericardiotomy due to Large Pericardial Effusion : A case report Dedy Irawan; Sasmojo Widito; Mohammad Saifur Rohman; Cholid Tri Tjahjono
Heart Science Journal Vol 2, No 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2021.002.04.9

Abstract

Background : Stent thrombosis is a serious complication following percutaneous coronary intervention (PCI), and dual antiplatelet therapy (DAPT) is necessary to avoid it. Surgery, on the other hand, is a common cause for stopping DAPT. Because patients were exposed to the possibility of a major adverse cardiovascular event (MACE) when DAPT was stopped, this circumstance poses a clinical dilemma.Objective : This case report aimed to describe the management of antithrombotic therapy in post PCI patient requiring DAPT who underwent pericardiostomy.Case : A 69-year-old woman with large pericardial effusion without cardiac tamponade, breast cancer on chemo- therapy, heart failure stage C NYHA functional class II, chronic coronary syndrome post-DES implantation at proximal-mid LAD, and hypertension. The patient underwent pericardiotomy procedures five days after DAPT discontinuation. For the bridging therapy, continuous UFH administration was initiated at a dose of 18 IU/kg/hour after the cessation of DAPT. The UFH dose was adjusted to achieve activated partial thromboplastin time (APTT) 1.5 to 2.0 times the control value. The UFH was discontinued 6 hours before surgery. After surgery, UFH infusion was restarted 6 hours after the confirmation of hemostasis. The administration of UFH then continued until three days after DAPT was restarted. No complications were found during and after the pericar- diostomy.Conclusion : We reported an antithrombotic treatment strategy in a post PCI patient undergoing pericardiostomy with discontinuation of DAPT, which was successfully treated with UFH without any complication. The UFH has been widely used in perioperative settings as a bridging therapy during the interruption of DAPT and may be considered in this condition. 

Page 6 of 31 | Total Record : 302

 4   5   6   7   8 

Filter by Year

2020 2025


Reset
Filter By Issues
All Issue Vol. 6 No. 4 (2025): The Pursuit of Precision: Navigating Risks, Refining Diagnosis, and Securing Lo Vol. 6 No. 3 (2025): Advancements in Cardiac Imaging : Unlocking New Perspectives on the Heart Visua Vol. 6 No. 2 (2025): The Complexity in the Management of Heart Rhythm Disorder Vol. 6 No. 1 (2025): Challenges in Managing Acute Heart Failure Vol. 6 No. Suppl_July (2025): Supplement Issue : Indonesian Acute Coronary Syndrome Summit in Conjun Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease Vol. 5 No. 3 (2024): The Science and Art of Revascularization in Acute Coronary Syndrome Vol. 5 No. 2 (2024): Challenges in the Management of Congenital Heart and Structural Heart Diseases Vol. 5 No. 1 (2024): Inflammation and Cardiovascular Disease Vol. 4 No. 4 (2023): The Science and Art of Caring for Critically III Patients in Intensive Cardiac Vol. 4 No. 3 (2023): The Essensial Role of the Metabolic Syndrome in the Development of Cardiovascul Vol 4, No 2 (2023): Dealing with the Complexity of the Wide Spectrum of Cardiovascular Disease Vol 4, No 1 (2023): Optimizing Outcome in Acute Cardiac Care Vol. 4 No. 1 (2023): Optimizing Outcome in Acute Cardiac Care Vol. 3 No. 4 (2022): Prevention, Screening dan Rehabilitation : The Back Bone of Quality Care Improv Vol 3, No 4 (2022): Prevention, Screening dan Rehabilitation : The Back Bone of Quality Care Improve Vol. 3 No. 3 (2022): Cardiovascular Disease in Young Adulthood: Who, When, and How to Screen? Vol 3, No 3 (2022): Cardiovascular Disease in Young Adulthood: Who, When, and How to Screen? Vol 3, No 2 (2022): Improving ST-Elevation Myocardial Infraction Patients Prognosis Vol 3, No 1 (2022): Assesment and Outcome of Coronary Artery Disease in the Reperfusion Era Vol 2, No 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease Vol 2, No 3 (2021): The Science and Art of Myocardial Revascularization Vol 2, No 2 (2021): Dealing with Vascular Disease Vol 2, No 1 (2021): How to Diagnose Heart Failure and Deal with The Treatment Complexity Vol 1, No 4 (2020): Acute Coronary Syndrome in Daily Practice : Diagnosis, Complication, and Managem Vol 1, No 3 (2020): Management of Coronary Artery Disease: From Risk Factors to The Better Long-Term Vol 1, No 2 (2020): The Assessment of Diagnostic and Treatment Modality in Heart Failure Vol 1, No 1 (2020): The Importance of Adherence to The Guidelines More Issue